Stockscreener 앱 받기
2.36
6.31%
0.14
Iovance Biotherapeutics Inc 주식(IOVA)의 최신 뉴스
What drives Iovance Biotherapeutics Incs stock priceTrade Entry Report & Community Consensus Stock Picks - baoquankhu1.vn
Trend Report: Will TNON benefit from seasonalityPortfolio Gains Summary & Stepwise Trade Execution Plans - baoquankhu1.vn
Dow Update: Can Iovance Biotherapeutics Inc deliver consistent EPS growthPortfolio Performance Report & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Analyst Boosts Iovance’s Price Target Amid Positive Market Moves - timothysykes.com
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Biotech Iovance offers 97,710 stock options to 17 new hires at $2.22 - Stock Titan
Iovance Biotherapeutics Stock Surges Amid Strategic Moves - StocksToTrade
Iovance Biotherapeutics (IOVA) Is Down 14.9% After Governance Scrutiny And Equity Raise Plan Is Revealed - Yahoo Finance
Iovance Biotherapeutics (IOVA) Valuation Check After Amtagvi Outlook Reaffirmation And Governance Concerns - Yahoo Finance
Iovance Biotherapeutics, Inc. (IOVA): A Bull Case Theory - Finviz
Iovance gets conditional Health Canada approval for Amtagvi - MSN
Aug EndMonth: Is Iovance Biotherapeutics Inc still a buy after recent gainsQuarterly Portfolio Review & Daily Growth Stock Tips - baoquankhu1.vn
The Bull Case For Iovance Biotherapeutics (IOVA) Could Change Following Reaffirmed 2025 Guidance And TIL Scale-Up - Sahm
She raised more than $1 billion for Iovance. Now, Maria Fardis has a new startup and a $200 million investment - The Business Journals
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Iovance Biotherapeutics, Inc. (IOVA), Nutex Health, Inc. (NUTX), Lantheus Holdings, Inc. (LNTH), and Molina Healthcare, Inc. (MOH) - GlobeNewswire
Moving Averages: Is Iovance Biotherapeutics Inc showing insider buying2025 Year in Review & Fast Gaining Stock Reports - baoquankhu1.vn
Published on: 2026-01-12 23:18:26 - Улправда
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Rating of "Hold" by Analysts - MarketBeat
Market Moves: How Iovance Biotherapeutics Inc stock performs in weak economyQuarterly Portfolio Report & Weekly Breakout Watchlists - Bộ Nội Vụ
Assessing Iovance Biotherapeutics (IOVA) Valuation After Revenue Guidance And 1,000 Patient Milestone - Sahm
Iovance Highlights Amtagvi Momentum and Confirms 2025 Guidance - The Globe and Mail
Why Iovance Biotherapeutics Inc. stock appeals to dividend seekersWeekly Stock Analysis & Accurate Intraday Trading Signals - Улправда
Iovance Biotherapeutics Inc. (IOVA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Iovance Biotherapeutics, Inc. Updates Corporate Presentation - TradingView — Track All Markets
Why Iovance Biotherapeutics Inc. stock remains resilientJuly 2025 Weekly Recap & Stepwise Swing Trade Plans - ulpravda.ru
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 7.4%What's Next? - MarketBeat
Why retail investors favor Iovance Biotherapeutics Inc. stockStock Price Forecasts & Low Cost Trading Plans - ulpravda.ru
Iovance Biotherapeutics (IOVA): Promising TIL Therapy Gains Momentum Amid Funding Challenges - MSN
Iovance Biotherapeutics (NASDAQ:IOVA) Trading Down 7.1%Here's What Happened - MarketBeat
Why Iovance Biotherapeutics Stock Got Mashed on Monday - MSN
Barclays Adjusts Valuation Targets for Iovance Biotherapeutics (IOVA) Amid Biotech Sector Review - Insider Monkey
Barclays adjusts valuation targets for Iovance Biotherapeutics (IOVA) amid biotech sector review - MSN
2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street - Finviz
Will Iovance Biotherapeutics Inc. stock attract more institutional investorsCovered Call Writing & Budget Friendly Investment Plans - bollywoodhelpline.com
Iovance Biotherapeutics: Bright Prospects For 2026 (NASDAQ:IOVA) - Seeking Alpha
The next front against cancer: A Mugglehead roundup - Mugglehead Magazine
Is Iovance (IOVA) Turning Talent Incentives and TIL Optimism Into a Durable Competitive Edge? - Sahm
Iovance Biotherapeutics (IOVA) Stock News Today: Barclays Raises Target, Short-Interest Pressure, and 2026 Catalysts (Dec. 23, 2025) - ts2.tech
Iovance Biotherapeutics: Is it Time to Invest? - StocksToTrade
Iovance Biotherapeutics (NASDAQ:IOVA) Trading Up 8.7%Still a Buy? - MarketBeat
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(4) - marketscreener.com
Will Iovance Biotherapeutics Inc. stock outperform Nasdaq indexTrade Analysis Summary & Community Verified Trade Signals - ulpravda.ru
Iovance Biotherapeutics, Inc. $IOVA Position Increased by Squarepoint Ops LLC - MarketBeat
Why Iovance Biotherapeutics Inc. stock attracts high net worth investors - DonanımHaber
How Iovance Biotherapeutics Inc. (2LB) stock valuation compares with sectorGap Down & Weekly High Return Stock Opportunities - DonanımHaber
4.73%
0.92%
자본화:
|
볼륨(24시간):